Skip to main content

Table 2 Multiple linear regression models displaying adjusted estimates for lnFGF19 for outcomes of arteriosclerosis parameters adjusted for the other clinical covariates in each model in patients with T2D

From: Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes

ModelsB (95% CI)βtpR2 for model
baPWV
 Model 0: unadjusted− 167.6 (− 227.0 to − 108.3)− 0.37− 5.57< 0.0010.135
 Model 1: age, sex, BMI and duration− 161.8 (− 218.7 to − 104.9)− 0.36− 5.61< 0.0010.241
 Model 2: Model 1 + SBP, DBP, hypertension, statins, NAFLD, NFS, UA, TC, TG, HDLC, LDLC, and Lpa− 98.7 (− 171.5 to − 26.0)− 0.22− 2.700.0080.587
 Model 3: Model 2 + ISHOMA-cp, HbA1c and antidiabetic treatments− 86.8 (− 164.5 to − 9.1)− 0.20− 2.230.0290.599
lnAIP
 Model 0: unadjusted− 0.22 (− 0.32 to − 0.12)− 0.30− 4.46< 0.0010.091
 Model 1: age, gender, BMI and diabetic duration− 0.21 (− 0.30 to − 0.11)− 0.28− 4.19< 0.0010.145
 Model 2: Model 1 + SBP, DBP, hypertension, statins, NAFLD, NFS, UA, TC, LDLC and Lpa− 0.21 (− 0.35 to − 0.07)− 0.29− 3.030.0030.342
 Model 3: Model 2 + ISHOMA-cp, HbA1c and antidiabetic treatments− 0.21 (− 0.36 to − 0.05)− 0.28− 2.660.0100.491